Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models

Tucker, ER; Jiménez, I; Chen, LD; Bellini, A; Gorrini, C; Calton, E; Gao, Q; Che, H; Poon, E; Jamin, Y; Da Costa, BM; Barker, K; Shrestha, S; Hutchinson, JC; Dhariwal, S; Goodman, A; Del Nery, E; Gestraud, P; Bhalshankar, J; Iddir, Y; Saberi-Ansari, E; Saint-Charles, A; Geoerger, B; Da Costa, MEM; Pierre-Eugène, C; Janoueix-Lerosey, I; Decaudin, D; Nemati, F; Carcaboso, AM; Surdez, D; Delattre, O; George, SL; Chesler, L; Tweddle, DA; Schleiermacher, G

Schleiermacher, G (通讯作者)，Inst Curie, Equipe SiRIC RTOP Rech Translat Oncol Pediat, INSERM U830, Lab Genet & Biol Canc, 26 Rue Ulm, F-75248 Paris, France.

CLINICAL CANCER RESEARCH, 2023; 29 (7): 1317

Abstract

Purpose: ALK-activating mutations are identified in approxi-mately 10% of newly diagnosed neuroblastomas and ALK ampli-fications in a further 1%-2% of......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索